Loading
  • Pipeline Pipeline
    • Pipeline Chart
    • uPAR-targeted radiopharmaceuticals
    • MNPR-101
      • Overview
      • Development Strategy
      • SNMMI Poster June 2024
      • EANM Presentation October 2024
    • Collaborations
      • Overview
      • Current Collaborations
    • Publications
      • MNPR-101
    • ALXN1840
      • EASL Poster May 2025
  • Investors Investors
    • Overview
    • Annual Meeting
    • News / Events
      • Press Releases
      • IR Calendar
      • In the News
      • Email Alerts
    • Company Information
      • Profile
      • Presentations
      • Our Team
      • FAQ
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Our Team Our Team
  • Careers Careers
  • Contact Us Contact Us
  • Home
  • Investors
  • News / Events
  • Press Releases
Investors

Investors

  • Overview
  • Annual Meeting
  • News / Events
    • Press Releases
    • IR Calendar
    • In the News
    • Email Alerts
  • Company Info
    • Profile
    • Presentations
    • Our Team
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Press Releases
  • IR Calendar
  • In the News
  • Email Alerts

Press Releases

Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments

Nov 12, 2021

Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma

Oct 27, 2021

Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma

Sep 16, 2021

Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe

Sep 13, 2021

Monopar Therapeutics to Present at Upcoming Investor Conferences in September

Sep 9, 2021

Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates

Aug 12, 2021

Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial

Aug 5, 2021

Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma

Aug 3, 2021

Monopar Appoints Octávio Costa, MD, as Chief Medical Officer

Jul 12, 2021

Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO

Jun 24, 2021
RSS
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • About
    • Pipeline
    • Investors
    • Our Team
    • Careers
    • Contact Us
    • Pipeline
    • Pipeline Chart
    • uPAR-targeted radiopharmaceuticals
    • MNPR-101
    • Collaborations
    • Publications
    • ALXN1840
    • Investors
    • Overview
    • Annual Meeting
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance

    Terms and Conditions of Use

    © 2025 Monopar Therapeutics Inc. All Rights Reserved.